Last reviewed · How we verify
Dutasteride plus tamsulosin
Dutasteride plus tamsulosin is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved.
Dutasteride plus tamsulosin, marketed by GlaxoSmithKline, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Dutasteride plus tamsulosin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms (NA)
- The Changes of Urine Growth Factors Level (EARLY_PHASE1)
- Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia (PHASE3)
- Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
- Prostate Medication, Metabolism and Gut Microbiota (PHASE4)
- Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia (PHASE3)
- Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH (PHASE3)
- Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dutasteride plus tamsulosin CI brief — competitive landscape report
- Dutasteride plus tamsulosin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Dutasteride plus tamsulosin
What is Dutasteride plus tamsulosin?
Who makes Dutasteride plus tamsulosin?
What development phase is Dutasteride plus tamsulosin in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing